![PDF) DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment PDF) DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment](https://i1.rgstatic.net/publication/331803174_DFN-02_Sumatriptan_10_mg_Nasal_Spray_with_Permeation_Enhancer_for_the_Acute_Treatment_of_Migraine_A_Randomized_Double-Blind_Placebo-Controlled_Study_Assessing_Functional_Disability_and_Subject_Satisfa/links/5c8cf51745851564fae0f5b8/largepreview.png)
PDF) DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment
![These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992 These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=sumatriptan-08.jpg&id=593165)
These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992
![These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992 These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=sumatriptan-09.jpg&id=593165)
These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992
![Dabigatran Market to Witness Huge Growth by 2028 | Pfizer, Bayer Healthcare, GlaxoSmithKline, Boehringer Ingelheim – Energy Siren Dabigatran Market to Witness Huge Growth by 2028 | Pfizer, Bayer Healthcare, GlaxoSmithKline, Boehringer Ingelheim – Energy Siren](https://energysiren.co.ke/wp-content/uploads/2022/01/Global-Dabigatran-Market-Including-Key-Players-Market-Share.jpg)
Dabigatran Market to Witness Huge Growth by 2028 | Pfizer, Bayer Healthcare, GlaxoSmithKline, Boehringer Ingelheim – Energy Siren
![These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992 These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=sumatriptan-06.jpg&id=593165)